184 related articles for article (PubMed ID: 21353530)
1. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer.
Otvos L; Kovalszky I; Riolfi M; Ferla R; Olah J; Sztodola A; Nama K; Molino A; Piubello Q; Wade JD; Surmacz E
Eur J Cancer; 2011 Jul; 47(10):1578-84. PubMed ID: 21353530
[TBL] [Abstract][Full Text] [Related]
2. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
3. Leptin signaling in breast cancer: an overview.
Cirillo D; Rachiglio AM; la Montagna R; Giordano A; Normanno N
J Cell Biochem; 2008 Nov; 105(4):956-64. PubMed ID: 18821585
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
5. Designer peptide antagonist of the leptin receptor with peripheral antineoplastic activity.
Beccari S; Kovalszky I; Wade JD; Otvos L; Surmacz E
Peptides; 2013 Jun; 44():127-34. PubMed ID: 23567149
[TBL] [Abstract][Full Text] [Related]
6. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.
Amemiya Y; Yang W; Benatar T; Nofech-Mozes S; Yee A; Kahn H; Holloway C; Seth A
Breast Cancer Res Treat; 2011 Apr; 126(2):373-84. PubMed ID: 20464481
[TBL] [Abstract][Full Text] [Related]
7. Regulation of estrogen receptors alpha and beta in human breast carcinoma by exogenous leptin in nude mouse xenograft model.
Yu W; Gu JC; Liu JZ; Wang SH; Wang Y; Zhang ZT; Ma XM; Song MM
Chin Med J (Engl); 2010 Feb; 123(3):337-43. PubMed ID: 20193256
[TBL] [Abstract][Full Text] [Related]
8. Obesity and the associated mediators leptin, estrogen and IGF-I enhance the cell proliferation and early tumorigenesis of breast cancer cells.
Lautenbach A; Budde A; Wrann CD; Teichmann B; Vieten G; Karl T; Nave H
Nutr Cancer; 2009; 61(4):484-91. PubMed ID: 19838920
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
10. Toward understanding the role of leptin and leptin receptor antagonism in preclinical models of rheumatoid arthritis.
Otvos L; Shao WH; Vanniasinghe AS; Amon MA; Holub MC; Kovalszky I; Wade JD; Doll M; Cohen PL; Manolios N; Surmacz E
Peptides; 2011 Aug; 32(8):1567-74. PubMed ID: 21723351
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
12. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer.
Palmieri D; Halverson DO; Ouatas T; Horak CE; Salerno M; Johnson J; Figg WD; Hollingshead M; Hursting S; Berrigan D; Steinberg SM; Merino MJ; Steeg PS
J Natl Cancer Inst; 2005 May; 97(9):632-42. PubMed ID: 15870434
[TBL] [Abstract][Full Text] [Related]
13. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome.
Chu QD; Panu L; Holm NT; Li BD; Johnson LW; Zhang S
J Surg Res; 2010 Apr; 159(2):689-95. PubMed ID: 19500800
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
15. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
16. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
17. A novel leptin antagonist peptide inhibits breast cancer growth in vitro and in vivo.
Catalano S; Leggio A; Barone I; De Marco R; Gelsomino L; Campana A; Malivindi R; Panza S; Giordano C; Liguori A; Bonofiglio D; Liguori A; Andò S
J Cell Mol Med; 2015 May; 19(5):1122-32. PubMed ID: 25721149
[TBL] [Abstract][Full Text] [Related]
18. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies.
Jardé T; Caldefie-Chézet F; Goncalves-Mendes N; Mishellany F; Buechler C; Penault-Llorca F; Vasson MP
Endocr Relat Cancer; 2009 Dec; 16(4):1197-210. PubMed ID: 19661131
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.
Zhang W; Wang L; Fan Q; Wu X; Wang F; Wang R; Ma Z; Yang J; Lu SH
Oncol Rep; 2011 Sep; 26(3):621-8. PubMed ID: 21687957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
